Focus: who reaps the benefits of biodiversity? by Karasov, C
Focus
C
all it bioprospecting, chemical pros-
pecting, gene-hunting, or natural
product research—the search for and
collection of wild plants and animal
products of potential value to medicine,
agriculture, cosmetics, and other uses
has been going on for hundreds, if not
thousands, of years. Today’s bioprospec-
tors are gathering and studying extracts
of everything from spider venoms to soil
microbes to algae. 
Bioprospecting had been shaping
global cultures for centuries before a
world trade organization came into
being. A quick tour of almost any gar-
den, farm field, or medicine cabinet
should serve as a reminder that the glob-
al economy has in part been built on
products of bioprospecting. According
to Joshua Rosenthal, deputy director of
the Division of International Training
and Research at the NIH Fogarty Inter-
national Center, more than 50% of the
most prescribed medicines in the United
States contain compounds derived from
natural products. And an even larger
percentage of the world’s people rely on
natural products for their primary medici-
nal needs. Until the past decade, however,
these natural products were collected
without compensating the communities
and governments of the source countries
where the products were found. 
For example, as recently as the 1980s,
the plant rosy periwinkle (Catharanthus
roseus) gave rise to two important drugs,
vinblastine and vincristine, which are
used to treat Hodgkin’s disease and child-
hood leukemia, respectively. Together,
the two drugs, manufactured primarily
by  Eli Lilly, net $100 million dollars
annually, yet the source countries have
never received a penny in royalties or
other compensation. 
However, the rules of collecting have
changed. For the first time in history,
bioprospectors are expected to compensate
source countries, thanks to the Conven-
tion on Biological Diversity (CBD),
signed at the 1992 United Nations Con-
ference on Environment and Develop-
ment in Brazil. The CBD was drafted in
response to concerns by international
organizations and governments about
the loss of global biodiversity and the
need for equitable sharing of benefits
from bioprospecting. This treaty set new
standards that more than 155 member
countries are expected to follow when
engaging in bioprospecting. 
A Blueprint for Bioprospecting
Throughout history most countries
considered biological resources to be the
common heritage of humankind, says
Richard S. Cahoon, vice president of
the Cornell Research Foundation and
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Passociate director of patents and technology
marketing at Cornell University in Ithaca,
New York. “This meant that there was no
law or moral obligation requiring a com-
pany that collected biological material
from another country to pay for access to
that material,” he says. “What has changed
is that we’ve begun to recognize property
rights in all biota. We also recognize how
bioprospecting can be used to encourage
economic development and conservation
in Third World countries.”
In effect, the CBD serves as a blueprint to
help countries and companies draft equitable
access and benefit-sharing agreements.  It also
offers a means for making conservation of
biodiversity economically beneficial. The
convention has three goals: the conservation
of biological diversity, the sustainable use of
its components, and the fair and equitable
sharing of the benefits from the use of genet-
ic resources. The CBD recognizes the inter-
dependence of countries controlling genetic
resources and those creating technologies that
make use of those resources. One of the key
articles (Article 15) of the convention states,
“Recognizing the sovereign rights of States
over their natural resources, the authority to
determine genetic resources rests with the
national governments and is subject to
national legislation.” Thus, individual coun-
tries, including signatories to the CBD, may
establish their own guidelines for setting up
equitable benefit-sharing agreements for con-
servation and rural development. Countries
can establish legislation regulating access to
genetic resources and, if they wish, require
payment for that access. Compensation can
be made in the form of money, royalties, or
support for conservation and local economic
development.
The CBD also requires that any company
or country collecting natural products
obtain the prior informed consent of the
source country. Countries may also exempt
any species from patenting or intellectual
property rights. 
Models of Benefit Sharing
In  the 10 years since the creation of the
CBD, a number of groups have explored
innovative ways to apply the convention’s
rules. Drug companies, universities, conser-
vation groups, government leaders, and
indigenous communities have formed
unlikely consortia trying to turn bio-
prospecting into a panoply of opportunities. 
One of the first bioprospecting groups
that attempted to implement the goals and
guidelines of the CBD was a collaboration
between the pharmaceutical firm Merck &
Company and Costa Rica’s Instituto
Nacional de Biodiversidad (INBio), a pri-
vate, nonprofit conservation and research
group. INBio agreed to provide Merck with
a limited number of plants, fungi, and other
samples from Costa Rica’s protected areas for
scientific and commercial evaluation. (INBio
was given special permission by the govern-
ment to follow relatively noninvasive collect-
ing procedures that did not disturb or
destroy protected habitat.) In return, Merck
would pay INBio $1 million every two years,
in addition to approximately $135,000 in
equipment and training in the first two years
of the deal. Merck also agreed to pay royal-
ties to InBio for any commercial products
that might result from the arrangement.
InBio pledged to give 50% of the royalties
and 10% of its total budget for bioprospect-
ing projects to the Costa Rican Ministry of
Environment and Energy to help finance a
national conservation program.
The InBio program is presented as a
model program in Biodiversity Prospecting:
Using Genetic Resources for Sustainable
Development, a 1993 publication of the
World Resources Institute. The book credits
not only INBio but also the Costa Rican
government for its efforts to create and
enforce the necessary legislation that allowed
for benefit sharing. One of the lessons
learned in the past decade by bioprospecting
groups, say the book’s authors, is that the
willingness and ability of a host country to
implement bioprospecting agreements is a
central factor in the success or failure of any
such agreement. 
Another organization that has explored a
number of approaches to improve the value
of benefit sharing is the International
Cooperative Biodiversity Groups (ICBG)
Program. This experimental effort, funded
by the U.S. government in partnership with
industry, seeks to integrate research in natu-
ral products drug discovery with efforts to
build scientific infrastructure and economic
capacity to enable conservation of biological
diversity in developing countries. 
The ICBG Program has three goals. The
first is to improve human health through
the discovery of new pharmaceutical, agri-
cultural, and veterinary agents to treat dis-
eases of importance in both developed and
developing countries. The second is to pro-
mote scientific and economic activity in
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Spider find.
A compound in
the  venom of black
widow spiders found in
the Negev Desert in Israel
may hold promise for treating
strokes.
Flower power. Rosy
periwinkle has given rise to drugs used to
treat childhood leukemia and Hodgkin’s disease.©
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less-developed countries by sharing the
benefits of drug discovery and conservation
research processes and products. And the third
is to conserve biological diversity through the
understanding and valuation of diverse bio-
logic organisms and the development of local
capacity to manage these resources.
ICBG projects have been conducted in
12 developing countries in Latin America,
Africa, and Asia. Some programs have
included extensive assistance in training and
infrastructure construction for such coun-
tries to develop their own pharmaceutical
industries. Others have developed extensive
incentive mechanisms for conservation by
governments and indigenous groups. 
To date, ICBG teams have collected and
tested more than 40,000 plant samples. The
teams have had many “hits” (possible leads to
new drugs), but it is still too soon to know if
any of these will lead to the actual develop-
ment of any new drugs. All but one of the
ICBG teams uses ethnobotanical informa-
tion from indigenous groups to identify
potential medicinal substances. (However,
most bioprospecting does not involve getting
information from shamans.) 
Just as important, the ICBG Program has
succeeded in creating several models for bio-
prospecting agreements that encourage local
economic development and conservation
within the regions where the bioprospecting
is conducted. For example, in Nigeria, ICBG
teams are screening traditional medicines
and other natural products for cures for
malaria and other diseases that affect devel-
oping nations—diseases that most western
pharmaceutical industries show little interest
in. In Suriname, the ICBG Program worked
in partnership with the Washington, DC-
based Conservation International to set up
an elaborate conservation trust fund called
the Forest People’s Fund. Conservation
International also acts as an intermediary,
helping scientists explore the traditional
medicines of two indigenous groups. 
When Is Bioprospecting Biopiracy?
When Athula Attygalle, director of the
Mass Spectrometry Facility at Cornell,
returned to his home country of Sri Lanka
a few years ago, he was greeted with photos
of himself on the front page of the national
newspaper captioned “herbal sucker” and
“is this bioprospecting research or racket?”
The chemist couldn’t understand his com-
patriots’ outrage. “I had come home to
arrange a formal bioprospecting program
with the government, similar to what InBio
did in Costa Rica,” he says. Attygalle points
out that it would have been much easier for
someone to actually steal samples—to take
a few handfuls of samples back in their
pockets. “Instead,” he says, “I was doing it
to help build the economy and biodiversity
conservation for my people.”
As promising as the CBD and benefit-
sharing agreements sound, bioprospecting
has become a hotbed of controversy over the
past decade, drawing attention from the
media and opposition from antiglobaliza-
tion groups. “Distrust is a problem,” says
Cahoon. “Some people think that bio-
prospecting agreements are inherently unfair
and outpriced for indigenous peoples from
the outset. They assume that the cards are
stacked against them.” In addition, although
the CBD is a legal document, as Rosenthal
explains, “It lacks bite. There is no way to
enforce it.” 
Bioprospecting is often painted by the
Action Group on Erosion, Technology, and
Concentration (ETC Group), a Winnipeg,
Manitoba–based conservation group, as a
north–south conflict, with people in the
technologically richer but genetically poorer
northern nations taking from the genetically
richer but technologically poorer southern
nations. In her 1997 book Biopiracy: The
Plunder of Nature and Knowledge, Vandana
Shiva, founder/director of the Research
Foundation for Science Technology and
Natural Resource Policy, a network of agri-
cultural and development researchers, speaks
of the CBD as “an initiative of the North to
globalize the control, management, and bio-
logical diversity of resources which lie prima-
rily in the Third World.”
Even the terms of bioprospecting are a
source of disagreement. The appropriation of
biological resources and knowledge through
patents and intellectual property rights with-
out fair compensation is considered biopiracy,
and the rosy periwinkle discoveries are fre-
quently cited by the media and in non-
governmental organization literature as exam-
ples. James S. Miller, curator and head of the
Applied Research Department at the
Missouri Botanical Gardens in St. Louis, con-
tends, however, that it’s unfair to label the
It had to be yew. The drug Taxol, made
from the bark of the Pacific yew, helps fight breast and ovarian cancers. rosy periwinkle discoveries or any other bio-
prospecting done before the CBD was signed
as biopiracy. It was, he says, just the normal
way of doing things. “There wasn’t anything
malicious or malevolent about it,” says Miller.
One of the most publicized recent attacks
on bioprospecting was made against an
ICBG team that was collecting and recording
indigenous medicinal plant knowledge of
Mayan healers in Chiapas, Mexico. The team
had a bioprospecting agreement with the
local Mayan healers, but not with healer
groups outside the immediate area. A con-
sortium of 11 other healer groups in the
region (with the help of the ETC Group)
opposed the project on the grounds that they
did not want commercial exploitation of
their traditional knowledge by outsiders. The
taint of heavily publicized biopiracy accusa-
tions forced the ICBG group leader, David
Berliner, to discontinue the group’s program
in Chiapas, and the issue of whether tradi-
tional knowledge qualifies as intellectual
property rights was not addressed. Such
rights continue to be a major obstacle to
resolving bioprospecting conflicts.
Who Owns Biodiversity?
When the CBD was signed in June of 1992
by 153 nations, the United States was the
only attending nation that refused to sign
the agreement. One of the major reasons
cited was concern over inadequate protection
of intellectual property rights for U.S.
biotechnology firms. Some U.S. officials felt
that the financial mechanism represented an
open-ended commitment with insufficient
oversight and control by the companies or
countries funding the bioprospecting. They
further felt that the benefit-sharing provi-
sions were incompatible with existing inter-
national regimes for intellectual scientific
research institute property rights, and that
the requirement to regulate the biotechnol-
ogy industry would needlessly stifle innova-
tion. President Clinton signed the CBD in
1999, but the U.S. Senate has yet to ratify
the agreement. Many feel that the lack of
U.S. participation in the CBD sends a poor
message to other nations about the intent of
the United States to share profits.
At  the heart of the controversy is the
global debate over patents and other intellec-
tual property rights. Such rights are legal
devices designed to confer ownership of
inventions and also determine the nature of
access to inventions and ideas. Drug and
agricultural companies depend on patents
and other intellectual property rights to pro-
tect their investment in product develop-
ment from natural products or otherwise.
“Yet many people are fundamentally opposed
to intellectual property rights,” says Cahoon.
“The almost intuitive thought is that [such a
right] is a bad idea because it allows us to pri-
vatize something that should be part of the
public good/public domain,” he says. “We
may think that all knowledge should be in
the public domain.”
Some of the most fervent objections to
bioprospecting come from activist groups
that equate bioprospecting and intellectual
property rights with biopiracy. Says Hope
Shand, research director of the ETC Group,
“Pharmaceutical corporations are winning
exclusive monopoly patents on someone else’s
knowledge and resources. Indigenous peoples
and farming communities have been devel-
oping these plants and other biological
resources for generations.” 
Many indigenous groups fear that they
will lose access to their own plants and tradi-
tional medicines if drug companies are
allowed to take out patents. Two recent cases
test this very concern. In 1996, a U.S. citizen
obtained a patent on a little yellow bean that
Mexicans have been eating for centuries.
According to the patent, Larry Proctor
brought a bag of mixed-color dry beans from
Mexico in 1994, picked out the yellow beans,
and planted them. He then claimed to have
invented a distinctively colored yellow seed.
The International Center for Tropical
Agriculture and the Mexican government are
challenging the U.S. patent on the grounds
that there is nothing new about the bean, so
the patent should never have been granted.
The next year, a Texas-based company
won a controversial patent on basmati rice
and grain lines. The patent applies to 22 bas-
mati varieties from Pakistan and India.
Basmati rice has been grown for centuries in
what was the Greater Punjab region, now
divided between India and Pakistan.
According to Shand, farmers from the area
are concerned that they will have to pay roy-
alties to the patent holder in order to grow
and sell their own rice.  However, India is not
contesting the patent because it is only for
select varieties of basmati rice and does not
affect the country’s overseas sales of basmati.
Educating Source Countries in
Bioprospecting
Educating both the governments and
citizens of source countries about bio-
prospecting can help them get a more real-
istic expectation of the benefits of bio-
prospecting so that they can make informed
decisions on whether to allow it or not.
“The danger in focusing on the big collab-
orations is that it raises the expectation of
the host countries,” says John Kilama, pres-
ident of the Global BioDiversity Institute, a
Wilmington, Delaware–based group that
teaches people in developing nations how
to benefit from bioprospecting programs.
“A lot of people expect that their countries
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One bean, two bean, yellow bean . . . Little
yellow beans from Mexico are the source of an
international biodiversity ownership debate.Focus •  Who Reaps the Benefits of Biodiversity?
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could get bioprospecting agreements with
big multimillion-dollar drug companies.
The truth is that most collaborations are
small and discoveries are infrequent. . . .
The last time a drug derived from natural
products reached the market was in the
nineteen-eighties, well before the CBD.”
Kilama, a former DuPont scientist, trains
leaders from developing countries in using
bioprospecting to support their local
economies and setting up conservation pro-
grams. The Global BioDiversity Institute has
held multiple month-long workshops across
Africa in the last two years to teach lawyers,
scientists, economists, and policy makers
about the business of biodiversity, benefit-
sharing agreements and contracts, intellectu-
al property rights, and biotechnology.
David Kingston, a professor of bioorganic
and natural products chemistry at Virginia
Polytechnic Institute and State University in
Blacksburg, has been teaching Surinamese sci-
entists how to extract chemicals from plants.
He sees bioprospecting as a win–win situation
for bioprospectors, public health, and source
countries when treaties are equitable. “The
host country has nothing to lose,” he says. “If
we find something, the host country gets roy-
alties. If we don’t find anything, they still have
all of the other resources we’ve invested in
their people, such as the conservation trust
fund, the training we gave their people, and
more than a million dollars’ worth of other
resources. This is all in exchange for allowing
us to collect plant samples. The United States
wins because we’ve gained new knowledge
about plant compounds. If we get a new drug
out of it, we win big.” But determining what
is equitable seems to be the biggest problem
plaguing the issue of bioprospecting.
“If an indigenous group understands what
its rights are and how to perfect and assert
them, it can choose to negotiate benefits or
refuse access,” says Cahoon. However, most
indigenous groups depend on having assis-
tance from the government or a concerned
intermediary group to help them understand
and assert their rights. “No one can be expect-
ed to sit down at the negotiating table with
leaders from a multinational organization
without support. Intermediaries are especially
important where the government is corrupt,”
says Cahoon. “Rights mean little in practice
unless they are clearly defined and strongly
defended by local and national governments.”
Still, indigenous information often does
not lend itself to global law. And as Cahoon
puts it, the current intellectual property right
laws “were designed for individuals inventing
gadgets in their garages, not for the wide vari-
ety of groups that are involved in bio-
prospecting property rights.” The Food and
Agriculture Organization of the United
Nations and the Consultative Group on
International Agricultural Research are two
groups working to develop new standards and
mechanisms to guide future international law
and practices in the area of bioprospecting.
Into the Next Decade
By one measure at least, the CBD has seen
success in its first decade: most nations now
expect bioprospectors to enter into benefit-
sharing agreements before delving into a
country’s natural products. The question
arises, though, whether bioprospecting
agreements, which can be both time-
consuming and costly, will have the effect
of discouraging bioprospecting and the
sometimes-resultant drug discovery. 
“Bioprospecting is not solely driven by
interest in money,” says Kingston. The hope
that cures to cancer, AIDS, and other diseases
are hidden in some endangered habitat still
fuels enthusiasm for bioprospecting, he says.
Kingston believes we can’t afford to stop look-
ing at natural products. “No chemist could
ever dream up the chemistry of Taxol,” he
says, referring to the drug for fighting breast
and other cancers that is derived from the bark
of the Pacific yew tree (Taxus brevifolia). 
Many people also support bioprospecting
as a “wonderful device to stimulate both inter-
nal economic development and conservation
at the same time,” says Lisa Famolare, senior
director for the Guianas at Conservation
International. Projects such as the ICBG
Program are just beginning to see the fruits of
the first 10 years of conservation and econom-
ic development efforts initiated since the CBD
came into effect. 
But the costs of bad publicity associ-
ated with accusations of biopiracy
can be high. Some scientists fear
that many pharmaceutical and
agricultural companies will
abandon bioprospecting in
favor of cheaper and less
controversial approaches
such as combinational
chemistry, which can
produce millions of
modestly priced com-
pounds. Combination-
al chemistry may also
be more attractive
because companies can
patent the by-products
without running the
risk of being labeled
“biopirates.”
However,  says Jerrold Meinwald, a
professor of chemistry at Cornell, “The
chemistry of natural products may give you
access to a much more diverse universe of
complex compounds than compounds creat-
ed through combinational chemistry. Nature
has had more than three billion years to cre-
ate its library of chemicals.” In Meinwald’s
experience, companies that have participated
in bioprospecting consortia seem to be sin-
cerely committed to the long-term goals of
conservation and helping local economies.
But money is still the bottom line.
The experience of Merck & Company
offers plenty of evidence that bioprospecting
can pay off, at least for the companies that
develop drugs. Last year, for example, sales
for just one of Merck’s drugs derived from
nature—the cholesterol-lowering treatment
Zocor, derived synthetically from a fermen-
tation product of Aspergillus terreus—
totaled $5.28 billion. The hope of the
drafters of the CBD is that, in the future,
bioprospecting will also pay off for the
source countries of natural products, the
people who may one day benefit from as-yet
undeveloped drugs, and the Earth itself, as
agreements are put into place to protect its
fragile and treasured resources.
Corliss Karasov
Against the grain? Patents
on basmati rice, which has been
grown in India for centuries, have
farmers worrying whether they can
plant. 
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